IL-34: Complete Research Profile — CSF1R and PTP-ζ Dual Receptor Biology, Microglial Identity Maintenance, Skin Langerhans Cell Homeostasis, Osteoclastogenesis Signaling, and Research Applications (2026)

# IL-34: Complete Research Profile — CSF1R and PTP-ζ Dual Receptor Biology, Microglial Identity Maintenance, Skin Langerhans Cell Homeostasis, Osteoclastogenesis Signaling, and Research Applications (2026)

Introduction

Interleukin-34 (IL-34) is the second known ligand for the colony-stimulating factor 1 receptor (CSF1R/CD115/M-CSFR), discovered by Lin et al. in 2008 through a functional receptor-binding screen of secreted proteins. Prior to this discovery, CSF1 (M-CSF) was believed to be the sole CSF1R ligand, making IL-34 the first cytokine to reveal that a type III receptor tyrosine kinase could accommodate structurally unrelated ligands with overlapping yet non-redundant biological functions.

IL-34 is encoded on chromosome 16q22.1 in humans and shares no amino acid sequence homology with CSF1 despite binding the same extracellular domain of CSF1R with comparable affinity. This structural divergence — IL-34 forms a non-covalent homodimer resembling a short-chain four-helix bundle, distinct from CSF1's elongated domain-swapped architecture — has been leveraged to dissect CSF1R biology in contexts where only one ligand is expressed. The discovery that IL-34 additionally signals through protein tyrosine phosphatase-ζ (PTP-ζ/PTPRZ1) and CD138 (syndecan-1) as alternative receptors opened a CSF1R-independent dimension of IL-34 biology with tissue-specific implications.

In the CNS, IL-34 is the predominant CSF1R ligand during embryonic microglial development and in adult microglial maintenance across many brain regions, while CSF1 takes precedence in peripheral myeloid populations. In the skin, IL-34 from keratinocytes drives Langerhans cell (LC) homeostasis in a spatially restricted manner. In bone, IL-34 promotes osteoclast differentiation and resorption activity. And in neurological disease, elevated IL-34 has been detected in cerebrospinal fluid and brain tissue in multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis, positioning it as both a biomarker and a mechanistic driver of neuroinflammatory myeloid responses.

This profile provides the mechanistic depth required for research investigators designing IL-34-centered experiments in neuroimmunology, skin biology, bone biology, or myeloid cell biology.

---

Molecular Structure and Receptor Binding

IL-34 Protein Architecture

Human IL-34 (UniProt Q6ZMJ4) is a 242-amino acid protein with:

• •Signal peptide (aa 1–28): ER targeting
• •Mature secreted chain (aa 29–242): 214 aa, ~39 kDa monomer; ~77 kDa homodimer under native conditions
• •Glycosylation: N-linked at N-75 and N-183; O-linked glycans in the C-terminal region; total apparent MW on SDS-PAGE ~55–65 kDa (monomer, glycosylated)
• •Homodimerization: non-covalent interface burying ~1,200 Ų; dimerization is required for high-affinity CSF1R binding

The crystal structure (PDB 4DKD; Ma et al., 2012) confirmed that IL-34 adopts a short-chain four-helix bundle topology (helices A-B-C-D) distinct from the long-chain helical bundle of CSF1. Despite this structural difference, IL-34 contacts CSF1R immunoglobulin-like domains D2 and D3 at overlapping but not identical epitopes to CSF1, explaining competitive binding behavior.

CSF1R: Shared Receptor Architecture

CSF1R (CD115) is a type III receptor tyrosine kinase with:

• •5 extracellular Ig-like domains (D1–D5)
• •IL-34 binding contacts primarily D2–D3; CSF1 contacts D1–D3
• •Transmembrane helix
• •Split kinase domain (JM/TK1/KI/TK2)
• •Key autophosphorylation sites: Y699 (SFK docking), Y721 (PI3K p85 docking), Y807 (activation loop), Y973 (GRB2)

Upon IL-34 binding, CSF1R undergoes receptor dimerization and transautophosphorylation at the same tyrosine residues as CSF1, activating identical canonical pathways: PI3K-AKT-mTOR (survival), RAS-MEK-ERK (proliferation), PLCγ-DAG-PKC (cytoskeletal remodeling), and STAT3/STAT5 (transcriptional).

PTP-ζ (PTPRZ1): A CNS-Specific Alternative Receptor

In 2012, Nandi et al. identified PTP-ζ (receptor-type tyrosine-protein phosphatase zeta, PTPRZ1) as a second functional IL-34 receptor expressed in the brain. PTP-ζ is a chondroitin sulfate proteoglycan receptor expressed on oligodendrocyte precursor cells (OPCs) and neurons but minimally on microglia. IL-34 → PTP-ζ signaling:

• •Inactivates PTP-ζ phosphatase activity (ligand-induced suppression mechanism)
• •Promotes OPC survival and differentiation via de-repression of phosphotyrosine substrates including β-catenin and FGFR
• •Provides a microglial-independent axis for IL-34 CNS activity

The PTP-ζ pathway has been implicated in CNS remyelination contexts — OPC-targeted IL-34 signaling via PTP-ζ may promote oligodendrocyte maturation independently of CSF1R-mediated myeloid effects.

CD138 (Syndecan-1) as Coreceptor

IL-34 contains a heparin-binding site (positively charged patch on helix A) enabling interaction with heparan sulfate proteoglycans. CD138 (syndecan-1), a cell surface HSPG, has been identified as an IL-34 coreceptor that enhances CSF1R signaling efficiency by concentrating IL-34 on cell surfaces. In multiple myeloma, tumor cell CD138 captures stromal IL-34 to activate CSF1R-driven survival signaling — a mechanism of particular interest for researchers studying myeloma-macrophage interactions in the TME.

---

Microglial Biology and CNS Maintenance

Embryonic Microglial Development

Microglia are brain-resident mononuclear phagocytes derived from yolk sac progenitors that colonize the CNS during embryogenesis (E8.5–E10.5 in mice). Two CSF1R ligands regulate distinct phases:

• •CSF1: dominates early yolk sac progenitor expansion and initial CNS colonization
• •IL-34: upregulated by neurons and astrocytes in the developing brain parenchyma; sustains microglial survival and proliferation from ~E12.5 onward

Wang et al. (2012) demonstrated that Il34-deficient mice had specific reductions in microglia (−40 to −60% in cortex and cerebellum) and Langerhans cells without affecting other tissue macrophage populations — establishing IL-34's non-redundant spatial specificity relative to CSF1.

Regional Brain IL-34 Expression

In the adult brain, IL-34 mRNA is expressed by neurons and astrocytes in a region-specific pattern:

• •Cortex and hippocampus: high IL-34 → dense microglial populations
• •Cerebellum: high IL-34 → abundant cerebellar microglia
• •Striatum: moderate IL-34; lower microglial density
• •White matter: relatively low neuronal IL-34; CSF1 predominates for white matter macrophage maintenance

This regional gradient creates a spatially encoded "microglial niche" where tissue-resident progenitor density tracks IL-34 availability. The homeostatic microglial transcriptome (P2RY12⁺, TMEM119⁺, SALL1⁺) is maintained in part by tonic IL-34 → CSF1R → MEK-ERK signaling that prevents default activation.

Microglial Homeostatic vs. Disease-Associated States

Homeostatic microglia (HAM) express high P2RY12, TMEM119, and CX3CR1, and are maintained by tonic CSF1R signaling from IL-34/CSF1. Following pathological stimuli (β-amyloid, DAMPs, demyelination), microglia transition to disease-associated microglia (DAM) states characterized by:

• •Downregulation of P2RY12, TMEM119
• •Upregulation of TREM2, ApoE, Spp1, CLEC7A, CD68
• •Shift from IL-34-dependent maintenance to CSF1-driven expansion

In neurodegeneration, IL-34 expression by neurons is paradoxically increased around amyloid plaques and degenerating neurons, potentially amplifying microglial recruitment into a DAM state that, when unresolved, can contribute to synaptic pruning and neuroinflammatory tissue damage.

---

Skin Langerhans Cell Homeostasis

IL-34 as the Epidermal LC Maintenance Factor

Langerhans cells (LCs) are specialized dendritic cells residing in the epidermis that express CSF1R and depend on local cytokine signals for maintenance. Unlike dermal macrophages that rely on both CSF1 and IL-34, epidermal LCs depend predominantly on keratinocyte-derived IL-34 for their homeostatic survival and self-renewal.

Wang et al. (2012) showed that Il34-deficient mice had a near-complete loss of epidermal LCs (>90% reduction) while dermal CD11b⁺ macrophages were preserved, demonstrating the exquisite spatial specificity of keratinocyte IL-34 for the epidermal compartment.

Keratinocyte IL-34 Regulation

Keratinocyte IL-34 expression is regulated by:

• •Constitutive Sp1/Sp3: basal epidermal IL-34 production
• •TNF-α and IL-1β: upregulate IL-34 in inflamed skin (atopic dermatitis, psoriasis contexts)
• •IL-17A: downregulates keratinocyte IL-34 in psoriasis — contributing to LC depletion observed in psoriatic plaques
• •TLR2/TLR4 activation (bacterial/fungal PAMPs): transiently upregulates IL-34 to boost LC surveillance capacity

LC Self-Renewal vs. Monocyte Replacement

Under steady-state conditions, LCs self-renew in situ via IL-34 → CSF1R → MEK-ERK-driven proliferation without monocyte input. After inflammatory LC depletion (contact hypersensitivity, UV irradiation), repopulation occurs in two phases:

1. Early (0–2 weeks): monocyte-derived LC precursors (CSF1R⁺, CX3CR1⁺) populate epidermis

2. Late (2–8 weeks): IL-34-sustained self-renewing LCs derived from local precursors replace monocyte-derived cells

This two-phase kinetics is relevant for investigators using LC depletion models (e.g., hDTR/DT injection in Langerin-DTR mice) combined with IL-34 neutralization to study LC reconstitution.

---

Osteoclastogenesis and Bone Remodeling

IL-34 and Osteoclast Differentiation

CSF1R is expressed on osteoclast precursors (CD14⁺ monocytes in humans; CD11b⁺ BM cells in mice). IL-34, like CSF1, supports osteoclastogenesis through:

• •Promotion of osteoclast precursor survival and proliferation
• •Upregulation of RANK (TNFRSF11A) on precursors, sensitizing them to RANKL-driven differentiation
• •Synergy with RANKL (TNFSF11): IL-34 + RANKL produces osteoclasts from human PBMCs with comparable efficiency to CSF1 + RANKL (Baud'huin et al., 2010)

In rheumatoid arthritis synovium, IL-34 is expressed by fibroblast-like synoviocytes (FLS) and contributes to local osteoclast-mediated bone erosion — a mechanistically distinct driver from systemic CSF1.

IL-34 in Periodontal Research Models

Periodontal ligament fibroblasts and gingival epithelial cells express IL-34, where it promotes local CSF1R⁺ macrophage and osteoclast activity in alveolar bone remodeling models. Investigators using LPS-stimulated periodontal cell cultures should account for IL-34 upregulation as a confound when interpreting CSF1-only data.

---

Neuroinflammatory Disease Contexts

Alzheimer's Disease

IL-34 expression is elevated in AD brain tissue (hippocampus, cortex) relative to age-matched controls, correlating with plaque burden and microglial activation markers. Key findings:

• •TREM2 signaling in microglia upregulates IL-34 production (autocrine CSF1R amplification)
• •Soluble TREM2 in CSF correlates with IL-34 levels — potentially reflecting a common microglial activation signature
• •IL-34 sustains plaque-associated microglial expansion but the net functional effect (protective clearance vs. pathological pruning) remains under active investigation

Multiple Sclerosis

IL-34 is elevated in CSF of MS patients relative to controls, and in demyelinated white matter lesions where it may drive CSF1R-dependent macrophage/microglial accumulation. Paradoxically, IL-34 → PTP-ζ signaling on OPCs may support remyelination, suggesting that the net IL-34 effect in MS depends on the relative CSF1R vs. PTP-ζ receptor balance in the lesion microenvironment.

ALS

Elevated plasma and CSF IL-34 has been reported in ALS patients, associated with microglial activation in the motor cortex and spinal cord. In SOD1-G93A mouse models, IL-34 expression tracks disease progression in spinal cord astrocytes — positioning it as a potential CSF biomarker for neuroinflammatory burden.

---

Transcriptional Regulation

Key Transcriptional Drivers

Promoter Architecture

The human IL34 promoter (~2 kb upstream TSS) contains:

• •NF-κB binding sites: primary inflammatory induction element
• •Sp1/GC boxes: constitutive basal expression in brain/skin
• •AP-1 (TRE) sites: responsive to PKC/MAPK signaling
• •CpG island around TSS: subject to methylation-dependent silencing in some tumor contexts

---

Experimental Protocols and Research Considerations

Recombinant IL-34 for In Vitro Studies

Commercial recombinant human IL-34 is available from R&D Systems (Cat# 5265-IL), PeproTech (Cat# 200-34), and BioLegend. Key considerations:

Reconstitution: Lyophilized IL-34 at 100 µg/mL stock in PBS + 0.1% BSA. IL-34 is a homodimer under native conditions; avoid conditions that disrupt non-covalent dimerization (low pH, high urea). Aliquot immediately; avoid >3 freeze-thaw cycles.

Working concentrations:

• •CSF1R phosphorylation (monocyte-derived macrophages): EC₅₀ ~1–10 ng/mL
• •Monocyte-to-macrophage differentiation: 50–100 ng/mL × 7 days (comparable to M-CSF 50 ng/mL)
• •Microglial proliferation (primary mouse microglia): 10–50 ng/mL
• •Osteoclastogenesis (PBMC + RANKL): 25–100 ng/mL IL-34 + 50 ng/mL RANKL × 14–21 days

Comparison to CSF1 (M-CSF): In CSF1R-expressing macrophage systems, IL-34 and CSF1 produce quantitatively similar proliferation, survival, and differentiation responses. To isolate IL-34-specific effects:

1. Use anti-CSF1R blocking antibody (clone AFS98, Invivogen) to confirm CSF1R dependence

2. In CNS contexts, use anti-PTP-ζ blocking antibody to separate PTP-ζ vs. CSF1R contributions

3. In skin/LC models, use IL-34-specific neutralizing antibody (R&D MAB5265) rather than anti-CSF1R which would also block CSF1

Measuring Endogenous IL-34

ELISA: R&D Systems Quantikine ELISA (D1L340) for human IL-34 in serum, plasma, CSF, conditioned medium. Sensitivity ~15 pg/mL. Note: IL-34 is present at low pg/mL in normal serum; CNS disease can elevate CSF IL-34 to 100–1,000 pg/mL range.

Multiplex: IL-34 is available in Luminex-based panels (e.g., Bio-Techne ProcartaPlex) for simultaneous measurement with CSF1, CCL2, and other myeloid-regulatory cytokines.

Microglial Differentiation Protocol from iPSCs

For investigators generating microglia from iPSCs where IL-34 is a key differentiation factor:

1. Differentiate iPSCs to primitive streak → lateral plate mesoderm (BMP4 + Wnt3a, day 0–4)

2. Induce yolk sac hematopoietic progenitors (VEGF + SCF, day 4–10)

3. Expand primitive macrophage precursors in M-CSF (25 ng/mL) + IL-3 (25 ng/mL), day 10–25

4. Microglial differentiation: transfer to TGF-β1 (50 ng/mL) + IL-34 (100 ng/mL) + CX3CL1 (100 ng/mL) for 14 days

5. Mature microglial markers: P2RY12⁺, TMEM119⁺, CX3CR1⁺, IBA1⁺, TREM2⁺

6. Validate: compare to CSF1 (100 ng/mL) control — IL-34 protocol yields higher P2RY12 expression in most published protocols (Muffat et al., 2016 modified)

IL-34 vs. M-CSF in microglial induction: IL-34-differentiated iPSC-microglia more closely resemble the homeostatic transcriptomic signature (higher SALL1, CX3CR1, P2RY12) compared to M-CSF-differentiated cells, likely reflecting the in vivo dominance of IL-34 in brain microglial maintenance.

LC Differentiation from CD34⁺ Progenitors

For Langerhans cell research:

1. Mobilize/isolate CD34⁺ HPCs from peripheral blood (G-CSF-mobilized or cord blood)

2. Culture in IMDM + 10% FBS + SCF (20 ng/mL) + GM-CSF (20 ng/mL) + FLT3L (20 ng/mL), day 0–7

3. Add TGF-β1 (0.5 ng/mL) + IL-34 (100 ng/mL) day 7–14 to drive LC commitment

4. Assess LC markers: CD1a⁺, CD207 (Langerin)⁺, EpCAM⁺, E-cadherin⁺

5. Control: replace IL-34 with M-CSF (50 ng/mL) — yields dermal macrophage phenotype instead of LC, confirming IL-34 specificity in epidermal DC commitment

CSF1R Inhibitor Controls

Investigators should always include CSF1R kinase inhibitors as controls to confirm receptor dependence:

• •PLX5622 (Plexxikon): CNS-penetrant CSF1R inhibitor widely used for microglial depletion in vivo (~1,200 ppm dietary); spares PTP-ζ signaling
• •BLZ945: CSF1R selective, IC₅₀ ~1 nM; used in vitro at 1–10 µM to block IL-34/CSF1 differentiation
• •Emactuzumab (RG7155): anti-CSF1R mAb; blocks both IL-34 and CSF1 binding; available as research reagent

---

IL-34 vs. CSF1: Key Distinctions for Experimental Design

This table guides experimental substitution decisions: in microglial culture, IL-34 better recapitulates in vivo maintenance biology; in bone marrow macrophage cultures, M-CSF is more physiological.

---

PubMed-Cited References

1. Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807-811. PMID: 18467591

2. Wang Y, Szretter KJ, Vermi W, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13(8):753-760. PMID: 22729249

3. Nandi S, Gokhan S, Dai XM, et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol. 2012;367(2):100-113. PMID: 22542597

5. Greter M, Lelios I, Pelczar P, et al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity. 2012;37(6):1050-1060. PMID: 23177320

6. Muffat J, Li Y, Yuan B, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22(11):1358-1367. PMID: 27668937

---

Summary for Research Investigators

IL-34 is a structurally unique CSF1R ligand that fills spatial gaps left by CSF1 — most critically in the CNS (microglial maintenance in cortex and cerebellum) and skin epidermis (Langerhans cell homeostasis). Its additional signaling through PTP-ζ on OPCs and CD138 on plasma cells/myeloma cells extends its biology beyond the myeloid compartment.

For experimental design, the critical distinctions are: (1) IL-34 more faithfully recapitulates brain-resident microglial identity than M-CSF in iPSC-microglia differentiation protocols; (2) LC differentiation from CD34⁺ HPCs requires IL-34 not M-CSF for epidermal DC commitment; (3) CNS IL-34 signaling has a CSF1R-independent PTP-ζ arm on OPCs that is missed when using CSF1R inhibitors alone as controls.

Investigators studying microglial biology in neurodegeneration, LC-mediated skin immunity, or bone remodeling should treat IL-34 and CSF1 as functionally overlapping but spatially non-redundant ligands whose independent manipulation reveals distinct biology inaccessible through CSF1R inhibition alone.

All materials described in this profile are for Research Use Only (RUO). Not for diagnostic, therapeutic, or human/animal administration purposes.